Idorsia effectively started its operations after demerging from Actelion on June 15, 2017, and registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange the next day. We may be young, but we have a 20-year heritage of drug discovery, a broad portfolio of innovative drugs, an experienced team of over 1,300 professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Find our latest financial updates, including our financial guidance in the financial overview.
Find out all about Idorsia's liquidity and debt structure.
We provide a full financial archive of our quarterly financial reports and related material.